What happened to compounded semaglutide

The short answer: compounded semaglutide was a product of a drug shortage, and when the shortage ended, so did the legal basis for mass-market copies. What remains in 2026 is a narrow exception for patients with a documented clinical need, a trail of FDA warnings, and branded cash prices that now overlap with what compounded product used to cost.

This is a trend piece about access and regulation. It does not cover dosing.

2022 to 2024: the shortage years

Semaglutide injection products were in shortage from 2022 because of increased demand. [1] While a drug is on FDA's shortage list, the federal compounding rules that normally bar pharmacies from making copies of commercially available drugs are relaxed. That opened the door to compounded semaglutide sold through pharmacies, med spas, and telehealth programs.

The market grew fast. A cross-sectional study of 79 websites selling compounded GLP-1 drugs, sampled between July and September 2024, found a median first-month price of 231 USD for compounded semaglutide and 330 USD for compounded tirzepatide. [5] The same study found that 50 of the 79 sites (63.3%) described their products with language such as "same active ingredient" as the brand, and 29 (36.7%) stated or implied the products were FDA approved. [5]

2023 to 2025: the warnings pile up

FDA began publishing concerns about compounded semaglutide while the shortage was still active. Its main points have been consistent:

• Salt forms. Some compounders used semaglutide sodium or semaglutide acetate. FDA says it has no information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug. [2]
• Dosing errors. FDA has received adverse event reports tied to dosing errors with compounded semaglutide, some requiring hospitalization, and reports of doses beyond what the approved label describes. [2]
• No premarket review. Compounded drugs are not FDA approved, and the agency does not verify their safety, effectiveness, or quality before they reach patients. [4]

As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA notes that state-licensed 503A pharmacies are not required to report adverse events, so these products are likely underreported. [2]

December 2024 to May 2025: the shortages end

Tirzepatide went first. FDA's final decision that its shortage was resolved came on December 19, 2024, with grace periods ending February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. [1]

On February 21, 2025, FDA determined that the semaglutide shortage was resolved. It gave 503A pharmacies until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to stop compounding products that are essentially a copy of the approved drug. [1] Every date is on the semaglutide regulatory timeline and the tirzepatide timeline. For tirzepatide, see our compounded tirzepatide guide.

After those dates, federal law puts compounders back under the ordinary rule. A 503A pharmacy may not regularly compound drugs that are essentially copies of a commercially available product, unless the prescriber determines that a change produces a significant difference for the individual patient. [3]

2026: enforcement shifts to marketing

With the shortage over, FDA's attention moved to how compounded GLP-1s are sold. On March 3, 2026, the agency announced warning letters to 30 telehealth companies. The problems it named included implying that compounded products are the same as FDA-approved drugs, presenting them as generics, and selling them under the telehealth firm's own branding in a way that obscured who actually made the drug. [6]

FDA has also warned telehealth companies for marketing unapproved molecules such as retatrutide directly to consumers. [2] That is a separate problem: those products are not compounded copies of an approved drug at all.

What access looks like now

Three things changed at once, and together they explain why compounded semaglutide faded:

1. The legal basis narrowed. Routine copies are no longer allowed. A compounded product now needs a documented patient-specific reason, such as an allergy to an inactive ingredient or a strength the manufacturer does not make. [3]
2. Branded cash prices fell. In September 2026 the manufacturer's self-pay pharmacy lists Wegovy tablets at 149 USD a month for the lowest strength and up to 299 USD for the highest, and the Wegovy pen at 349 USD a month after an introductory offer. [7] That overlaps with the 2024 compounded range.
3. Medicare opened a door. From July 1, 2026, eligible Medicare Part D enrollees can get Wegovy injection or tablets for a 50 USD monthly copay under the Medicare GLP-1 Bridge, with prior authorization. [8]

The full price picture, including insurance and telehealth program fees, is on the semaglutide cost page. State rules for telehealth prescribing and pharmacy licensing are in our state legal guides. For the wider picture across every drug in the class, see the GLP-1 hub.

What to watch

The shortage list is the switch. If semaglutide or tirzepatide returned to FDA's shortage list, the shortage-based compounding allowance could return with it. Until then, the questions to ask any program offering compounded semaglutide are simple: what is the documented clinical reason, which licensed pharmacy is making it, and what exactly is the active ingredient.